T he seriousness of alcohol withdrawal and its widespread occur rence in the 166 Veterans Administration hospitals in the 1960's was the principal reason this pivotal study was conducted. The important work by Kaim and colleagues has endured over the years, because alcohol withdrawal still is common, potentially life threatening, and often not recognized and treated promptly and effectively.
Kaim and colleagues studied the ef ficacy of four drugs-chlordiazepoxide (a benzodiazepine), chlorpromazine ( a n e u r o l e p t i c o r a n t i p s y c h o t i c agent), hydroxyzine (a sedating anti histamine), and thiamine (a vitamin)-commonly used at that time to treat alcohol withdrawal symptoms, specifi cally the more serious symptoms of delirium tremens and convulsions. These researchers' results help estab lish the benzodiazepines as drugs of choice in treating alcohol withdrawal. To fully understand the context in which Kaim and colleagues conducted their study, it is useful to consider the state of pharmacological treatment of withdrawal at that time.
D u r i n g t h e 1 9 5 0 ' s a n d e a r l y to mid1960's, several initial studies suggested that promazine and chlorpro mazine (both antipsychotic medica tions) were effective in treating alcohol withdrawal. Later studies did not con firm these findings. Moreover, several subsequent studies suggested that the incidence of serious withdrawal symp toms, such as seizures and delirium, might actually be higher after adminis tration of these two agents (Sereny and Kalant 1965) . Pharmacologically, based on today's knowledge, compli cations such as confusion and delirium would be expected. These tranquilizing agents decrease the seizure threshold by making the brain more susceptible to spontaneous cellular electrical activ ity. The agents also have properties (i.e., anticholinergic) that disrupt cellu l ar commu nic atio n, re su l t i ng i n changes in body function (e.g. gas trointestinal disorders).
C hlo rd i az ep o xid e w as a no th er medication studied by Kaim and col leag ues in thei r article. Chlordia zepoxide was marketed in 1961. It is interesting to note that in that same year, Kaim and Rostenstein (1961) opined that based on clinical evidence, Librium [chlordiazepoxide], in higher dosage of 200 to 300 mg, daily, brings prompt and gratifying control of both the psychotic and convulsive phenomena without the toxicity experienced with the use of phenothiazines, reserpine, or even the barbiturates (see Kaim et al. 1969 Kaim et al. , p. 1641 .
The research evidence to support this statement was first pre sented orally by the authors in 1967 and then published in this 1969 report. Presumably, these early clinical impressions provided the stimulus for Kaim and colleagues' more formal study on the four agents.
Another agent examined by Kaim and colleagues was thi amine. It may seem curious now that thiamine, a vitamin, was in cluded as a test drug in this study. However, in the 1960's, there still was debate as to the contribution of the combination of alcohol and poor nutrition to withdrawal state. Because many alco holics do not eat a wellbalanced diet, it was believed that nutri tional deficiencies, such as thiamine, might be related to the severity of withdrawal and its complications. It was only in 1956 that Isbell first demonstrated that abrupt discontinuation of alco hol administration in wellnourished individuals still was fol lowed by alcohol withdrawal and seizures (Isbell et al. 1955) .
In the 1960's, controversy also existed as to whether early treat ment of alcohol withdrawal symptoms would prevent the progres sion to delirium tremens (Sellers and Kalant 1976) . In their article, Kaim and colleagues suggested that early treatment could indeed halt the progression of the withdrawal state. Similarly, the etiology of seizures during withdrawal was uncertain (i.e., could seizures be prevented?). Kaim and coworkers found that chlordiazepoxide de creased the risk of seizures (compared with placebo) and chlorpro mazine increased this risk. Based on these findings, the researchers deduced that the seizures that developed during alcohol withdrawal resulted from a general neuroadaptive change in the brain caused by the withdrawal of alcohol. Such changes could be modified by pharmacological factors and varied among individual patients.
Several important aspects have continued to set Kaim and col leagues' work apart from that of other researchers. For example:
• The size of the study was quite large (557 patients)-no study, before or after, has been larger.
• The study was conducted in "real life" clinical care settings across the United States.
• A significant number of patients in the study who received only a placebo (nonactive medication) had positive treatment outcomes. Such successful outcomes demonstrated what a powerful treatment simple supportive care could be in some patients. Indeed, Sellers and colleagues (1983) , among others, confirmed a highplacebo response in terms of subjective symptoms (e.g., anxiety) and nonserious physical signs (e.g., tremor). However, the placebo was not effective in decreasing the risk of serious complications (e.g., seizures, delirium).
• The apparent progression of alcohol withdrawal to the more seri ous delirium tremens was prevented by chlordiazepoxide. Incidentally, it is interesting to speculate that the results of this study probably understate the efficacy potential of chlordiaze poxide because the patients received only 50 mg every 6 hours, administered intramuscularly and orally. A more flexible dosing schedule with higher doses might well have shown better effica cy. Furthermore, chlordiazepoxide injections administered intra muscularly probably resulted in rather low and initially inconsistent levels of the drug in the blood.
• As mentioned earlier, chlorpromazine increased the risk of seizures during alcohol withdrawal. According to Sellers and coworkers (1983) , treatment of alcohol withdrawal syndrome with a benzodiazepine is rarely associated with seizures.
• Kaim and colleagues used appropriate clinical criteria to identify and diagnose alcohol withdrawal (i.e., gastrointestinal distress, sweating and flushing [increased autonomic activity], insomnia, tremor, irritability, apprehension, depression, and clouded senso ry perception or confusion). Since the 1960's, quantitative re finements have been made in defining these criteria more precisely (e.g., the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised and the manual's fourth edi tion); still the clinical criteria established by Kaim and col leagues have been largely validated (Sellers et al. 1991) . However, in the study by Kaim and colleagues, a graded mea sure of alcohol withdrawal severity was not used; consequently, differences in the patient's time of response to each drug were not seen, and the results of the study probably present a conser vative estimate of the differences among the drugs.
If an experiment similar to the one conducted by Kaim and col leagues was performed today, the study would likely include a more detailed characterization of the patients; the use of a validated and standardized measure of alcohol withdrawal, such as the revised Clinical Institute Withdrawal Assessment of Alcohol scale (CIWA-Ar) (Sullivan et al. 1989) ; a data presentation to show the patient's time of response to each drug; statistical analysis to deter mine the likelihood that the patient would experience complications or that the patient would have a successful treatment outcome; and the use of a strategy that allows researchers to administer more medi cation to patients earlier in the treatment (Sellers et al. 1983) . Finally, considering what is known about thiamine today, it is unlikely that a 1995 trial would include this vitamin. Even the use of a placebo con trol group would be controversial because of the substantial risk that nondrugtreated patients might develop serious complications.
Apart from the general lessons imparted by the work of Kaim and colleagues and by others in the field, it is likely that this seminal arti cle had still another major impact on the treatment of patients. It cre ated within the Veterans Administration system an increased awareness of, and interest in, treating alcohol withdrawal effectively. From a broader perspective, benzodiazepines have continued to be the drugs of choice for alcohol withdrawal since shortly after the publication of the seminal paper (Sellers and Kalant 1976) . Although refinements have been made in measurement, dose schedules, trial designs, and data analysis, the clinical trial results of Kaim and col leagues in this seminal article have been confirmed repeatedly in clinical practice since 1969. Furthermore, many of the observations have been incorporated into "clinical pearls" (e.g., always treat a pa tient experiencing alcohol withdrawal with a benzodiazepine first be fore you give a neuroleptic if the patient is hallucinating). We now know that some patients may need a drug such as haloperidol (a drug similar to chlorpromazine) in addition to benzodiazepine to fully treat their withdrawal. 
